CONCURRENT PILOT STUDIES IN GIANT CELL ARTERITIS AND TAKAYASUS ARTERITIS TO EXAM

巨细胞动脉炎和高安动脉炎的同步试点研究

• 批准号: 8354738
• 负责人: AVERY GOTTFRIED
• 金额: $ 139.6万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-08-15 至 2013-04-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8354738
• 关键词: Adverse effects; Blood Vessels; Blood specimen; Cells; Disease; Effectiveness; Glucocorticoids; Inflammation; Inflammatory; Laboratory Research; Life; Pharmaceutical Preparations; Pilot Projects; Play; Prednisone; Recurrence; Research; Rheumatoid Arthritis; Role; Safety; Symptoms; T-Lymphocyte; Takayasu' s Arteritis; Temporal Arteritis; Vasculitis; Work; improved; prevent

This study will examine whether the medication abatacept is safe in the treatment of giant cell arteritis (GCA) and Takayasu's arteritis (TAK) and whether there is evidence of effectiveness to support pursuing this medication in larger scale studies. During the course of this study, blood samples will be obtained for research purposes to examine the mechanisms that occur in GCA and TAK and the effects of atabacept. GAC and TAK are diseases that share a number of common features and are both characterized by blood vessel inflammation (vasculitis) that can be serious or even life threatening. While glucocorticoid medications, such as prednisone, can improve the symptoms of GCA and TAK, these are associated with significant side effects and they do not prevent disease recurrences in most people. Abatacept is a medication that is currently approved for the treatment of rheumatoid arthritis. Abatacept is believed to work by interfering with the action of inflammatory cells called activated T cells. Evidence form laboratory research has supported that activated T cells may play a role in the blood vessel inflammation seen in GCA and TAK. Because of this information and the need to identify better treatment for GCA and TAK, conducting a study to explore the safety and possible effectiveness of abatacept is an appropriate next step.

这项研究将检查药物阿atacept是否在治疗巨细胞炎（GCA）和高山动脉炎（TAK）方面是否安全，以及在大规模研究中是否有效力支持追求这种药物的有效性。在这项研究过程中，将获得血液样本以研究GCA和TAK中发生的机制以及Atabacept的影响。 GAC和TAK是具有许多共同特征的疾病，既有血管炎症（血管炎）的特征，这些疾病可能严重甚至威胁生命。虽然糖皮质激素药物（例如泼尼松）可以改善GCA和TAK的症状，但它们与显着的副作用有关，并且不能阻止大多数人的疾病复发。 Abatacept是一种目前批准用于治疗类风湿关节炎的药物。据信，阿atacept通过干扰称为活化T细胞的炎症细胞的作用来起作用。实验室研究的证据表明，活化的T细胞可能在GCA和TAK中看到的血管炎症中起作用。由于这些信息以及需要确定GCA和TAK更好的治疗方法，因此进行一项研究以探索Abatacept的安全性和可能有效性是适当的下一步。